Imexpharm Corporation

HOSE:IMP Stock Report

Market Cap: ₫7.3t

Imexpharm Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Dao Tran

Chief executive officer

₫5.0b

Total compensation

CEO salary percentagen/a
CEO tenure11.6yrs
CEO ownershipn/a
Management average tenure5.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

CEO

Dao Tran (72 yo)

11.6yrs

Tenure

₫5,032,239,598

Compensation

Ms. Dao Thi Tran has been General Director at Imexpharm Corporation since May 2013 and serves as its Member of Executive Board. Ms. Tran had been Vice Chairwoman of the Board of Directors at Imexpharm Phar...

Leadership Team

NamePositionTenureCompensationOwnership
Dao Tran
General Director11.6yrs₫5.03bno data
Tuan Ngo
Deputy General Director & Member of Executive Board9.8yrs₫2.43bno data
Nhung Huynh
Deputy General Director & Member of Executive Boardno data₫2.03bno data
Phuong Van Le
Deputy General Director & Member of Executive Boardno data₫2.99bno data
Le Kim Nguyen
Secretary of the Board of Directors9.4yrs₫442.47mno data
Duy Nguyen
Deputy General Directorless than a yearno datano data
Thanh Nguyen
Deputy General Director & Member of Executive Boardless than a yearno datano data
Hung Hoang
Chief Accountant & Directorless than a yearno datano data

5.2yrs

Average Tenure

48yo

Average Age

Experienced Management: IMP's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dao Tran
General Directorno data₫5.03bno data
Hung Hoang
Chief Accountant & Directorless than a yearno datano data
Vinh Thi Han
Non-Executive Director6.7yrs₫644.00mno data
Hung Truong
Non-Executive Director4.6yrs₫644.00mno data
Suyong Chung
Director1.7yrs₫284.31mno data
Woo Sung
Chairperson of the Boardno datano datano data

3.1yrs

Average Tenure

50yo

Average Age

Experienced Board: IMP's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 10:16
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imexpharm Corporation is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Minh DangSSI Securities Corporation
Quan CaoViet Dragon Securities Corporation